Opportunities
Search

The integration of Artificial Intelligence (AI) and Biological Research has the potential to pave the way for breakthroughs in biotechnology and bio-system design that will create innovations, new industries, and jobs. To capitalize on this promise, the Directorate for Biological Sciences (BIO) will make awards for Postdoctoral Research Fellowships in Biology (PRFB) to recent doctoral degree recipients, for proposals with a research and training focus at the Intersection of Artificial Intelligence and Biological Sciences to Strengthen and Safeguard Biotechnology Innovations. Applying AI to highly complex biological systems will reveal unknown mechanisms in the natural world that hold promise for technological developments. Candidates with AI and/or biology experience will develop deep expertise in both by proposing additional training in both areas. These combinations of current expertise and new cross-training will produce scientists who work seamlessly at the intersection of AI and biology. The fellows are expected to become field leaders who use AI capabilities to extrapolate from biological data to technological advances. Proposers are encouraged to consider how to leverage the nation’s diversity of existing biological data, and biological infrastructure, such as Biofoundries, Programmable Cloud Labs, Manufacturing USA Institutes, and NEON, to accelerate discovery, innovation and the biotechnology that improves human lives, promotes the U.S. economy, and benefits the nation.

The Analysis Program supports research in analysis. Areas of current activity include complex, harmonic, and real analysis; dynamical systems and ergodic theory; functional analysis; mathematical physics; operator theory and operator algebras; partial differential equations and calculus of variations. Conferences Proposals to the Analysis Program for conferences or workshops must be submitted through the program solicitation "Conferences and Workshops in the Mathematical Sciences" (link below). Principal Investigators should carefully read the solicitation to obtain important information regarding the substance of proposals for conferences, workshops, and similar activities. To facilitate timely notification of the availability of support, proposals for conferences, workshops, and similar activities should be submitted 8 months in advance of the start date of the proposed event.

The U.S. Department of Labor’s (DOL) Veterans’ Employment and Training Service (VETS) supports local Stand Down events that assist veterans experiencing homelessness by providing a wide range of employment, social, and health services.Stand Down is a military term referring to an opportunity to achieve a brief respite from combat. Troops assemble in a base camp to receive new clothing, hot food, support services, and a relative degree of safety before returning to combat action. A DOL VETS-funded Stand Down event serves a similar purpose; however, it is intended for veterans experiencing or at-risk of homelessness. The critical services provided at these events are often the catalyst that enables those individuals to reenter the workforce. VETS awards these noncompetitive grants on a first-come, first-served basis to support one-day or multi-day events at up to $7,000 or $10,000, respectively. They are collaborative events coordinated between VA, DOL, other federal, state, and local government agencies and community-based organizations providing services and supplies to veterans experiencing and at risk of homelessness. In the event of a federal disaster declaration, VETS will accept applications up to $50,000 to conduct Stand Down events in the impacted areas.VETS awards Stand Down grants subject to the availability of federal funding. All costs incurred by the award recipient prior to the period of performance start date identified in the Notice of Award issued by the Department are incurred at the recipient’s own expense. 

This solicitation applies to six (of the nine) CHE Disciplinary Research Programs: Chemical Catalysis (CAT); Chemical Measurement and Imaging (CMI); Chemical Mechanism, Function and Properties (CMFP); Chemical Synthesis (SYN); Environmental Chemical Sciences (ECS); and Macromolecular, Supramolecular and Nanochemistry (MSN). All proposals submitted to these six CHE Disciplinary Research Programs (other than the following exceptions) must be submitted through this solicitation, otherwise they will be returned without review. Exceptions: Faculty Early Career Development Program (CAREER) proposals should be submitted through the CAREER solicitation (https://www.nsf.gov/funding/pgm_summ.jsp?pims_id=503214) by the CAREER deadline date specified. Facilitating Research at Primarily Undergraduate Institutions: Research in Undergraduate Institutions (RUI) and Research Opportunity Awards (ROA) proposals should be submitted through the RUI/ROA solicitation (https://www.nsf.gov/funding/pgm_summ.jsp?pims_id=5518) during the window for the appropriateCHE Disciplinary Research Program. In addition to the requirements of the RUI program, proposals should follow the guidance in this solicitation. Proposals for Early-concept Grants for Exploratory Research (EAGER), Grants for Rapid Response Research (RAPID), Research Advanced by Interdisciplinary Science and Engineering (RAISE), and conferences can be submitted anytime after consultation with the cognizant NSF Program Officer. Supplemental funding requeststo existing grantscan be submitted anytime after consultation with the cognizant NSF Pro...

The Universe is the ultimate laboratory, and we can now probe it as never before through several powerful and diverse windows – electromagnetic waves, high-energy particles, and gravitational waves. Each of these windows provides a different view. Together they reveal a detailed picture of the Universe that will allow us to study matter, energy, and the cosmos in fundamentally new ways. The “Windows on the Universe” Multi-Messenger Astrophysics (WoU-MMA) program identifies three categories of messengers - electromagnetic waves, high-energy particles including neutrinos and cosmic rays, and gravitational waves. The goals of WoU-MMA are to build the capabilities and accelerate the synergy between observations and theory to realize integrated, multi-messenger astrophysical explorations of the Universe. The WoU-MMA program welcomes proposals in any area of research supported through the participating divisions that address at least one of the following criteria: Coordination: Activities to coordinate observations involving more than one messenger. Observations: Observations of astrophysical objects or phenomena that are potentially sources of more than one messenger. Interpretation: Theory, experiment, simulations and other activities to understand or interpret observations of astrophysical objects that are sources of more than onemessenger. Competitive proposals will accelerate the progress in multi-messenger astrophysics and advance the community activities that have been developed during the initial five-year period of the WoU-MMA program. These build on observational and an...

This Notice provides Tribes with program requirements and instructions on how to apply for Indian Community Development Block Grant (ICDBG) Imminent Threat (IT) funding. This Notice also increases ceilings for ICDBG-IT grants. How to Submit Your Application:You must email your ICDBG-IT application to: ONAP-ICDBG@hud.gov Also send a copy to your ONAP Area Office.Important: Do not submit your ICDBG-IT application through Grants.gov. Applications sent through Grants.gov will not be accepted.

Summary: The fiscal year 2026 (FY26) Breast Cancer Research Program (BCRP) Breakthrough Award mechanism supports promising research with high potential to lead to or make breakthroughs in breast cancer. All applications must address at least one of the FY26 BCRP overarching challenges or provide adequate justification for exception. Applications must address the challenge in a way that can lead to a breakthrough and have major impact. The FY26 Breakthrough Award mechanism contains four different funding levels designed to support major (but not all) stages of research that will lead to clinical application. Each level specifies a distinct research scope. This program announcement discusses the Breakthrough Award Level 3.Distinctive Features:·        For this funding mechanism, small-scale clinical trials are allowed but not required. Applications proposing projects with a clinical trial should be submitted under the Clinical Trial option.·        The research team must include two or more breast cancer consumer advocates.·        This funding mechanism allows for a single Principal Investigator (PI), or two partnering PIs referred to as the Initiating PI and the Partnering PI. For the Partnering PI Option (PPIO), only the Initiating PI will submit a pre-application, but both PIs will need to submit at the full application stage. Be advised, failure to submit all associated (Initiating and Partnering PI) applications by the deadline may result in administrative withdrawal.

Summary: The fiscal year 2026 (FY26) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Pilot Clinical Trial Award (PCTA) supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of amyotrophic lateral sclerosis (ALS). Projects may range from phase 1 to small-scale phase 2 trials.Applications must address one of the following focus areas:·        Biomarker-Driven Interventions: Disease-modifying interventions, with mechanism-specific biomarkers to predict which clinical trial participants are likely to respond, demonstrate target engagement, and effects on the intended biological pathway.·        Clinical Care: Improving aspects of clinical care and symptom management for ALS.Distinctive Features: Funding from this award mechanism must support a clinical trial. The clinical trial should begin no later than 12 months after the award date or 18 months for U.S. Food and Drug Administration (FDA)-regulated studies.Projects proposing a therapeutic intervention (drug, biologic, and/or device) must incorporate biomarkers specific to the intervention into the trial design.All pre-applications and applications are required to incorporate community collaboration, as described in Section 3.2.2, to optimize research impact.Applications must include a detailed Regulatory Strategy plan that outlines the approach for obtaining regulatory approvals, if required, specifically for the funded portion of the study. In addition, applications must provide a separate Transition Plan that describes how the outcomes of t...

Summary: The fiscal year 2026 (FY26) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Therapeutic Development Award (TDA) supports research ranging from preclinical validation of therapeutic leads through U.S. Food and Drug Administration (FDA) Investigational New Drug (IND)-enabling studies. The proposed studies are expected to be empirical in nature and product-driven. Applicants with limited amyotrophic lateral sclerosis (ALS) experience are strongly encouraged to include collaborators with substantial experience in the relevant ALS model systems, endpoints and pathophysiology.Applications supported by this award must begin with lead compounds in hand and must already demonstrate proof-of-concept efficacy data in at least one appropriate preclinical model system of ALS, including whole-animal and cellular model systems.Distinctive Features: Mechanism-specific, predictive/cohort-selective, target engagement and pharmacodynamic biomarker development, in parallel to the main therapeutic effort, is a critical component of the FY26 ALSRP Therapeutic Development Award. If appropriate mechanism-specific biomarkers are already available or currently in development, how the existing biomarkers will improve trial design, patient selection, and efficiency or interpretation of the proposed ALS therapeutic approach must be apparent in the application. Development of biomarkers for the purposes of diagnosis, prognosis, or measurement of general disease progression without consideration of the therapeutic development process will not be supported.Therapeutic candidates which have...

Summary: The fiscal year 2026 (FY26) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Clinical Outcomes and Biomarkers Award (COBA) supports the development and/or validation of clinical outcomes and biomarkers to enrich clinical trials in amyotrophic lateral sclerosis (ALS). Projects can be relevant to a specific therapy, a class of therapeutics, or to a specific ALS subtype (such as a particular genetic mutation) and do not have to broadly apply to all patients.Distinctive Features: To meet the intent of the funding opportunity, applications may address clinical biomarkers and/or clinical outcomes. This may include the identification, development, and/or validation of promising biomarkers for ALS, which may include, but are not limited to susceptibility/risk, diagnostic, monitoring/disease progression, prognostic, predictive, response, or safety biomarkers. Clinical Outcomes projects may focus on the identification, development, and/or validation of clinician-, observer-, or patient-reported, and/or performance outcome measures for ALS. Projects may include the optimization of current outcome measures already in use.Applications may utilize digital health measures, including wearable devices, smart-phone sensors, video or voice recordings, imaging studies, or other devices which record disease-relevant physiological data and/or outcomes.Community Collaboration is an important element of the FY26 ALSRP COBA. Applicants will be expected to articulate how the proposed research question or study design was informed by theALS lived experience community.

Summary: The fiscal year 2026 (FY26) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Therapeutic Idea Award (TIA) supports new, innovative, high-risk, high-gain ideas aimed at amyotrophic lateral sclerosis (ALS) drug or therapy discovery. The studies supported by this award mechanism are expected to be hypothesis-driven and generate preliminary data for future avenues of therapeutic investigation.Distinctive Features: Potential impact and innovation are important features of the TIA. Applications may demonstrate the ability to achieve interpretable results in the absence of preliminary data supporting the hypothesis. While the inclusion of preliminary data is not prohibited, the strength of the application should rely on the approach.

With a focus on two-year Institutions of Higher Education (IHEs), the Advanced Technological Education (ATE) program supports the education of technicians for the high-technology fields that drive our nation's economy. The program involves partnerships between academic institutions (grades 7-12, IHEs), industry, and economic development agencies to promote improvement in the education of science and engineering technicians. It is strongly recommended that projects be faculty-led and required that courses and programs are credit-bearing, although materials developed may also be used for incumbent worker education. Materials may also be adapted and implemented as credit-bearing courses. The ATE program supports curriculum development; professional development of college faculty and secondary school teachers; career pathway development for both students and incumbent workers; and other activities including applied research projects that advance the knowledge base related to technician education. The ATE program encourages partnerships with other entities that may impact technician education. For example, with the National Institute of Standards and Technology (NIST) Manufacturing Extension Partnerships (MEPs) (http://www.nist.gov/mep/index.cfm) as applicable to support technician education programs and the industries they serve; and Manufacturing USA Institutes(https://manufacturing.gov/) addressing workforce development issues. The ATE program encourages proposals from Minority Serving Institutionsas well as other institutions that support the recruitment, retention, and comp...

Summary: Created in FY23, the Ovarian Cancer Clinical Trial Academy (OCCTA) supports the next generation of Early-Career Investigators (ECIs) in clinical trial research to produce effective treatments and cures for ovarian cancer. The OCCTA, through its Leadership, provides for professional and leadership development of the ECIs to include skills and competencies needed to execute clinical trials, providing intensive mentoring, national networking, collaborations, and a peer group for junior clinical trialists. The OCCTA will bring together established investigators (the Academy Dean and Assistant Dean), established Career Guides (mentors), and a group of ECIs/Scholars to conduct successful, highly productive clinical trials in ovarian cancer.Distinctive Features: Research funded under this FY26 funding opportunity will support translational research and small-scale, early-phase clinical trials in ovarian cancer. Preliminary data are required, however, these data do not necessarily need to be derived from the ovarian cancer research field. The ECI must be within 12 years of their last postdoctoral research position (Ph.D.), clinical fellowship (M.D.), or equivalent at the time of full application submission deadline. The ECI must commit no less than 25% effort to this award and/or OCCTA activities for the first two years. The Designated Mentor must be a clinical trialist with a strong record of mentoring and training early-career investigators.

Summary: The Ovarian Cancer Pilot Award supports research that expands or modifies current thinking about and/or approaches in ovarian cancer, exploring innovative concepts or theories in ovarian cancer that could ultimately lead to critical discoveries or major advancements that will drive the field forward.Distinctive Features: Innovation is key. Research projects that demonstrate exceptional scientific merit but lack innovation do not meet the intent of the mechanism. Preliminary data are not required but are allowed for this mechanism.This mechanism includes a blinded pre-application component. Pre-applications to this funding opportunity will undergo a blinded pre-application screening. While preparing your pre-application, do not include any material that may identify the PI, a collaborator, or the organization of the PI or collaborator.

Summary: The OCRP Clinical Trial Award supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of ovarian cancer.Distinctive Features: Clinical trials may be designed to evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance and/or emerging approaches and technologies. Proposed projects may range from small proof-of-concept trials (e.g., pilot, first-in-human, phase 0) to demonstrate the feasibility or inform the design of more advanced trials through large-scale trials to determine efficacy in relevant patient populations.

Summary: Initially created in FY09, the OCRP Ovarian Cancer Academy (OCA) is a unique, interactive virtual academy providing intensive mentoring, national networking, collaborations, and a peer group for junior faculty. The overarching goal of the OCA is to conduct innovative and impactful ovarian cancer research while developing successful, highly productive ovarian cancer researchers in a collaborative research and career development environment.Distinctive Features: The OCA is a virtual career development and research training platform that consists of Early-Career Investigators (ECIs), their Designated Mentors, and an Academy Dean and Assistant Dean. The OCA-ECI Award is not a traditional career development award; the ECI is expected to participate in monthly webinars and annual workshops and to communicate and collaborate with other members of the Academy (other ECIs, Mentors, the Dean and Assistant Dean) as well as with the advocacy community.

Summary: The Ovarian Cancer Research Program (OCRP) Investigator-Initiated Research Award is intended to support high-impact research that addresses a critical need and has the potential to make an important contribution to ovarian cancer or patient/survivor care.Distinctive Features: Application must contain strong research plan with sound scientific rational and logical reasoning. Preliminary data are required. Research projects may focus on any phase of research, from basic laboratory research through translational research, excluding clinical trials.Partnering Principal Investigator (PI) Option: The Partnering PI Option is structured so that two investigators, each of whom will be designated as a PI, will work synergistically on a single project. The results of this partnering project should significantly advance the research beyond what would be possible through individual efforts.

The EDU Core Research (ECR) program offers this ECR:Core solicitation and invites proposals for fundamental research (curiosity-driven basic research and use-inspired basic research) that contributes to the general, explanatory knowledge that underlies STEM education in one or more of the three broadly conceived Research Areas: Research onSTEM Learning and Learning Environments, Research on Broadening Participation in STEM fields, andResearch on STEM Workforce Development. Within this framework, the ECR program supports a wide range of fundamental STEM education research activities, aimed at learners of all groups and ages in formal and informal settings. Fundamental researchgenerates knowledge and understanding with the potential for broad relevance. The potential implications of ECR fundamental research for improving STEM education practice may be indirect and long-term rather than direct and immediate. Moreover, whether they include basic or use-inspired basic research, all successful ECR:Core proposals focus on the advancement or refinement of foundational knowledge for STEM education. The amount of funding and duration requested in proposals submitted to the ECR:Core solicitation should align with the maturity of the proposed work and the size and scope of the empirical effort. The solicitation has three levels of funding with a range of budget sizes, and proposals may request a duration of 3 to 5 years for any level: (1)Level I proposals may request up to $500,000; (2)Level II proposals may request up to $1,500,000; (3)Level III proposalsmay request up to $2,500,000.....

This is a Notice of Funding Opportunity (NOFO) for a Limited Competition that will invite application(s) from eligible organization(s) to apply. Please see Section III. Eligibility for additional information. The purpose of this NOFO is to seek applications in a limited competition for the Eunice Kennedy Shriver Intellectual and Developmental Disabilities Research Centers (IDDRCs). This NOFO invites applications to undergo peer review for research center grants designed to advance the diagnosis, prevention, treatment, and amelioration of intellectual and developmental disabilities (IDD) and is limited to IDDRCs funded under RFA-HD-20-016 or RFA-HD-21-009. In accordance with NIH standard peer-review processes, the application(s) will be peer-reviewed, and only meritorious application(s) will be considered for funding.This NOFO seeks applications from institutions that meet the qualifications for a multidisciplinary program of IDD research that will include: 1) 3-4 total Cores that facilitate interdisciplinary and translational research in IDD and its dissemination, and that support IDD-related projects funded by other sources; and 2) at least two and no more than three specific research projects related to one of several areas identified as areas of research need in IDD. Collaborative investigations combining expertise in translational science, biomarker assessment, outcome measure development, tool validation, bioinformatics, and therapeutic development will be encouraged. Funds for the majority of outside research projects using these core facilities come from independent....

Summary: The fiscal year 2026 (FY26) Peer Reviewed Cancer Research Program (PRCRP) Impact Award supports mature research that will have a near-term impact on clinical cancer care in one of the congressionally directed FY26 PRCRP Topic Areas. Applicants must consider how the research project will lead to the advancement of knowledge in cancer research, patient care and/or treatment options in the Military Health System (MHS).Distinctive Features:• Applications must include preliminary data to support feasibility of the study.• Projects must have strong potential to result in a near-term impact in cancer.• The funding mechanism allows clinical trials.• This funding mechanism allows for a single Principal Investigator (PI), or two partnering PIs referred to as the Initiating PI and the Partnering PI. Only the Initiating PI will submit a pre-application, but both PIs will need to submit full applications. The Partnering PI’s application is an abbreviated package specific to their distinct portion of the research project. Be advised, both applications for a research project may be withdrawn if the initiating or partnering application is rejected or administratively withdrawn.

Summary: The fiscal year 2026 (FY26) Peer Reviewed Cancer Research Program (PRCRP) Idea Award (IA) supports innovative, untested, high-risk/potentially high-reward concepts, theories, paradigms, and/or basic cancer research. The advancement of knowledge in cancer research, patient care, and/or treatment options in the Military Health System (MHS) is critical to Service Members, Veterans, other military beneficiaries and the American public.Distinctive Features: The proposed project should demonstrate creative thinking and innovation.• Incremental advances, the next logical step, or switching a model system from one cancer to another cancer are not appropriate for this award.• Inclusion of preliminary data is not required; however, the project must be based on strong scientific rationale.• New for FY26: Early Career Investigator Option: The Early Career Investigator option is designed to support the continued development of promising independent investigators that are early in their faculty appointments.

Summary: The fiscal year 2026 (FY26) Peer Reviewed Cancer Research Program (PRCRP) Clinical Trial Award (CTA) supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of cancer within at least one of the FY26 PRCRP Topic Areas. Clinical trials proposed may evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance, and/or emerging approaches and technologies. Proposed projects may range from small proof-of-concept trials (e.g., pilot, first-in-human, phase 0) that evaluate the effects of interventions or inform the design of more advanced trials to large-scale trials (up to phase III) to determine efficacy in relevant patient populations.Distinctive Features:• Applications to this award mechanism must include a clinical trial.• Projects can range from phase 0 to phase III.• If an Investigational New Drug (IND) application, Investigational Device Exemption (IDE), or equivalent, is required, a regulatory application must be submitted to the relevant regulatory agency by the Clinical Trial Award application submission deadline. The regulatory application should be specific to the product and indication to be tested in the proposed clinical trial.• Applications are required to include patient advocates.• Animal studies are NOT allowed under this award mechanism. All preclinical work must be completed prior to the award start date.

HBCU-UP provides awardsto strengthen STEM undergraduate education and research at Historically Black Colleges and Universities (HBCUs).Support is available through thefollowing tracks: Targeted Infusion Projects (TIP), which provide support to achieve a short-term, well-defined goal for enhancing and innovating undergraduate STEM education at an HBCU. Research on Broadening Participation in STEMprojects (BPR), which provide support for researchthat seeks to create and study new theory-driven models and innovations related to the participation and success of underrepresented groups in STEM undergraduate education, especially African Americans. Research Initiation Awards (RIA), which provide support for STEM faculty with no prior or recent research funding to pursue research at the home institution, another research-intensive institution, an NSF-funded research center, or a national laboratory. Implementation Projects (IMP), which provide support to design, implement, study, and assess comprehensive institutional efforts for increasing the number of students receiving undergraduate degrees in STEM and enhancing their preparation by strengthening STEM education and research. Broadening Participation Research Centers (BPRC),which provide support to create centers that conduct research on STEM education and broadening participation and build the intellectual infrastructure to facilitate the creation, integration, and transfer of new knowledge. Other Funding Opportunities include EArly-Concept Grants for Exploratory Research (EAGER), Rapid Response Research (RAPID), conference, a...

Summary: The fiscal year 2026 (FY26) Pancreatic Cancer Research Program (PCARP) Translational Research Partnership Award supports partnerships between clinicians, population scientists, applied scientists and/or basic scientists that will accelerate the movement of promising ideas in pancreatic cancer toward clinical applications. The partnership must include at least one member with expertise in pancreatic cancer research or pancreatic cancer patient care. All applications must address at least one of the FY26 PCARP Focus Areas. ·        This award mechanism requires preliminary data to support feasibility of the research hypothesis(es) and research approaches. However, these data do not necessarily need to originate from studies of pancreatic cancer. Applications can support retrospective tissue analysis, correlative studies and pilot clinical trials; however, this mechanism does not allow large-scale clinical trials. ·        The Translational Research Partnership Award requires two Principal Investigators (PIs) referred to as the Initiating PI and the Partnering PI. Only the Initiating PI will submit a pre-application, but both PIs will need to submit at the full application stage. The partnering PI’s application is an abbreviated package specific to their distinct portion of the research project. Be advised, all associated applications for a research project may be withdrawn if the initiating or partnering application is rejected or administratively withdrawn.

Summary: The fiscal year 2026 (FY26) Pancreatic Cancer Research Program (PCARP) Focused Pilot Award supports the exploration and development of impactful and innovative concepts under a patient-centered focus area of pancreatic cancer research that could ultimately lead to major advancements that will have a profound effect on patients’ overall quality of life. The research this award supports should strive to produce robust preliminary data that can serve as a foundation for future clinical or real-world research application. Distinctive Features: This award mechanism allows, but does not require, preliminary data. Applications can support clinical research studies; however, this mechanism does not allow clinical trials. Preclinical animal studies do not meet the intent of this mechanism.